Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
768 | 3003 | 54.8 | 92% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
40 | 31853 | AIDS RESEARCH AND HUMAN RETROVIRUSES//HIV 1//AIDS |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | IAVI NEUTRALIZING ANTIBODY | Address | 154 | 87% | 2% | 75 |
2 | DUKE HUMAN VACCINE | Address | 77 | 46% | 4% | 125 |
3 | HIV AIDS VACCINE IMMUNOL IMMUNOGEN DISCOVER | Address | 70 | 78% | 2% | 46 |
4 | INT AIDS VACCINE INITIAT NEUTRALIZING ANTIBODY CT | Address | 69 | 83% | 1% | 39 |
5 | VACCINE | Address | 34 | 12% | 9% | 265 |
6 | BROADLY NEUTRALIZING ANTIBODIES | Author keyword | 33 | 75% | 1% | 24 |
7 | HUMORAL PONSE PATHOGENS | Address | 27 | 92% | 0% | 11 |
8 | CD4 BINDING SITE | Author keyword | 23 | 79% | 0% | 15 |
9 | NEUTRALIZING ANTIBODIES | Author keyword | 22 | 17% | 4% | 115 |
10 | IMMUNOL MICROBIAL SCI | Address | 21 | 15% | 4% | 129 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | BROADLY NEUTRALIZING ANTIBODIES | 33 | 75% | 1% | 24 | Search BROADLY+NEUTRALIZING+ANTIBODIES | Search BROADLY+NEUTRALIZING+ANTIBODIES |
2 | CD4 BINDING SITE | 23 | 79% | 0% | 15 | Search CD4+BINDING+SITE | Search CD4+BINDING+SITE |
3 | NEUTRALIZING ANTIBODIES | 22 | 17% | 4% | 115 | Search NEUTRALIZING+ANTIBODIES | Search NEUTRALIZING+ANTIBODIES |
4 | GP120 | 19 | 16% | 4% | 111 | Search GP120 | Search GP120 |
5 | 4E10 | 18 | 83% | 0% | 10 | Search 4E10 | Search 4E10 |
6 | 2F5 | 15 | 71% | 0% | 12 | Search 2F5 | Search 2F5 |
7 | 2G12 | 15 | 73% | 0% | 11 | Search 2G12 | Search 2G12 |
8 | MPER | 14 | 59% | 1% | 16 | Search MPER | Search MPER |
9 | GP41 | 14 | 20% | 2% | 62 | Search GP41 | Search GP41 |
10 | BROADLY NEUTRALIZING ANTIBODY | 12 | 59% | 0% | 13 | Search BROADLY+NEUTRALIZING+ANTIBODY | Search BROADLY+NEUTRALIZING+ANTIBODY |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CD4 BINDING SITE | 397 | 86% | 7% | 204 |
2 | PROXIMAL EXTERNAL REGION | 277 | 76% | 6% | 194 |
3 | HUMAN MONOCLONAL ANTIBODY | 209 | 34% | 17% | 500 |
4 | GP120 | 147 | 28% | 15% | 453 |
5 | BROADLY NEUTRALIZING ANTIBODIES | 136 | 62% | 5% | 139 |
6 | HUMAN MONOCLONAL ANTIBODIES | 135 | 29% | 13% | 395 |
7 | ENV CLONES | 130 | 80% | 3% | 82 |
8 | CD4 BINDING | 129 | 72% | 3% | 103 |
9 | MUCOSAL SHIV CHALLENGE | 118 | 95% | 1% | 39 |
10 | 2F5 | 114 | 86% | 2% | 59 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy | 2014 | 49 | 149 | 82% |
Antibodies in HIV-1 Vaccine Development and Therapy | 2013 | 84 | 101 | 88% |
Insights into the trimeric HIV-1 envelope glycoprotein structure | 2015 | 4 | 58 | 93% |
Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies | 2012 | 109 | 112 | 87% |
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | 2004 | 502 | 145 | 74% |
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | 2005 | 596 | 108 | 73% |
GP120: Target for neutralizing HIV-1 antibodies | 2006 | 272 | 172 | 78% |
HIV-1 neutralizing antibodies: understanding nature's pathways | 2013 | 60 | 179 | 78% |
The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein | 2015 | 4 | 59 | 59% |
The Role of Antibodies in HIV Vaccines | 2010 | 172 | 226 | 69% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | IAVI NEUTRALIZING ANTIBODY | 154 | 87% | 2.5% | 75 |
2 | DUKE HUMAN VACCINE | 77 | 46% | 4.2% | 125 |
3 | HIV AIDS VACCINE IMMUNOL IMMUNOGEN DISCOVER | 70 | 78% | 1.5% | 46 |
4 | INT AIDS VACCINE INITIAT NEUTRALIZING ANTIBODY CT | 69 | 83% | 1.3% | 39 |
5 | VACCINE | 34 | 12% | 8.8% | 265 |
6 | HUMORAL PONSE PATHOGENS | 27 | 92% | 0.4% | 11 |
7 | IMMUNOL MICROBIAL SCI | 21 | 15% | 4.3% | 129 |
8 | NEUTRALIZING ANTIBODY | 21 | 78% | 0.5% | 14 |
9 | SCRIPPS HIV AIDS VACCINE IMMUNOL IMMUNOGEN | 21 | 85% | 0.4% | 11 |
10 | RETROVIRAL BIOL | 15 | 77% | 0.3% | 10 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000197345 | ENFUVIRTIDE//GP41//T 20 |
2 | 0.0000162400 | HIV 1 GP41//GP120 CD4 INTERACTION//CD4 RECEPTOR |
3 | 0.0000157950 | UNITE RETROVIROL MOL//ENTROPY EVOLUTION RATE//HIV 1 MOTHER TO CHILD TRANSMISSION |
4 | 0.0000119044 | ANTI R7V ANTIBODIES//C ADE//T CELL INFECTION |
5 | 0.0000114967 | SIV//SHIV//SIMIAN IMMUNODEFICIENCY VIRUS |
6 | 0.0000110223 | PARTNERS AIDS//HIV PATHOGENESIS PROGRAMME//DORIS DUKE MED |
7 | 0.0000108599 | CCR5//MARAVIROC//CCR5 ANTAGONIST |
8 | 0.0000104292 | HGP 30//VACCINE DEV BRANCH//HIV 1 IMMUNOGEN |
9 | 0.0000093871 | CYANOVIRIN N//CV N//ACTINOHIVIN |
10 | 0.0000080842 | ELECTRON ION INTERACTION POTENTIAL//INFORMATIONAL SPECTRUM METHOD//DECEPTIVE IMPRINTING |